ERYDERM Drug Patent Profile
✉ Email this page to a colleague
When do Eryderm patents expire, and what generic alternatives are available?
Eryderm is a drug marketed by Arbor Pharms Inc and is included in one NDA.
The generic ingredient in ERYDERM is erythromycin. There are one hundred and three drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the erythromycin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Eryderm
A generic version of ERYDERM was approved as erythromycin by TORRENT on July 6th, 2020.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ERYDERM?
- What are the global sales for ERYDERM?
- What is Average Wholesale Price for ERYDERM?
Summary for ERYDERM
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 103 |
| Patent Applications: | 4,166 |
| DailyMed Link: | ERYDERM at DailyMed |
US Patents and Regulatory Information for ERYDERM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arbor Pharms Inc | ERYDERM | erythromycin | SOLUTION;TOPICAL | 062290-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
